Quick Answer
Mirum Pharmaceuticals, Inc. reported Cash and Equivalents of $296.68 million for fiscal year 2025.
Mirum Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $296.68M | +33.3% |
| 2024 | $222.50M | -22.3% |
| 2023 | $286.33M | +922.5% |
| 2022 | $28.00M | -10.6% |
| 2021 | $31.34M | -77.9% |
| 2020 | $142.09M | +1087.0% |
| 2019 | $11.97M | -77.0% |
| 2018 | $51.96M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $282.02M | +26.5% | +23.6% |
| June 30, 2025 | $228.12M | -2.2% | +7.7% |
| March 31, 2025 | $211.82M | -30.1% | -4.8% |
| December 31, 2024 | $222.50M | -22.3% | -0.2% |
| September 30, 2024 | $222.97M | -26.4% | -4.4% |
| June 30, 2024 | $233.25M | -21.5% | -23.0% |
| March 31, 2024 | $302.84M | +512.8% | +5.8% |
| December 31, 2023 | $286.33M | +922.5% | -5.5% |
- Mirum Pharmaceuticals, Inc. showed an increase of +33.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Mirum Pharmaceuticals, Inc.’s cash and equivalents has grown by 471.0% (from $51.96 million to $296.68 million).
- The most recent figure is from Mirum Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: